Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its ...

R&D Expenses: Research and development expenses for the year ended December 31, 2024 decreased to approximately $2,044,000 ...

As U.S. stock markets continue to recover, with major indices closing higher for the third consecutive day, investors are cautiously optimistic about the potential easing of tariffs and its impact on ...

McGill University researchers have demonstrated that AMPA receptors (AMPARs), which mediate fast excitatory neurotransmission ...

Transfect the cells with the recombinant vector using Lipofectamine ... Use the cells on the coverslip to check the level of GFP fusion protein expression with high-resolution fluorescence ...

Strong revenue performance, including approximately $1.9 million milestone and license revenue recognized in 2024Up to $7.5 million in grants awarded from CEPI and Gates Foundation intended to acceler ...

This study provides a potentially useful investigation into the positive role of BDNF/TrkB signaling in implanted dental pulp stem cells to enhance dentin regeneration in the context of dental caries.

BEIJING, China I March 24, 2025 I SineuGene Therapeutics Co., Ltd. ("SineuGene"), a clinical-stage biotech company pioneering innovative therapies for ...

Creative Diagnostics has announced its comprehensive Drug Discovery Services for antiviral therapeutic development. NEW YORK, NY, UNITED ST ...

Monoclonal antibodies lead biosimilar approvals because of their large market size, well-defined regulatory pathways, and ...

DYAI READ THE FULL DYAI RESEARCH REPORT Dyadic International Inc. (NASDAQ:DYAI) announced 2024 results and listed a number of accomplishments that will bring both product and grant revenue in the next ...

This infographic highlights the key advantages of CHO cells and the technologies that are pushing the boundaries of cell ...